Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Durvalumab with or Without Tremelimumab in Combination with Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial

Solange Peters,Byoung Chul Cho,Alexander V. Luft,Jorge Alatorre-Alexander,Sarayut Lucien Geater,Konstantin Laktionov,Dmytro Trukhin,Sang-We Kim, Grygorii M. Ursol,Maen Hussein,Farah Louise Lim,Cheng-Ta Yang,Luiz Henrique Araujo,Haruhiro Saito,Niels Reinmuth, Caitlin Lowery,Helen Mann,Ross Stewart,Haiyi Jiang,Edward B. Garon,Tony Mok, Melissa L. Johnson

JOURNAL OF THORACIC ONCOLOGY（2025）

Cited 1|Views12
Key words
Tremelimumab,Durvalumab,POSEIDON,Meta- static NSCLC,Five-year overall survival
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined